These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26484998)

  • 21. New oral anticoagulants for non-valvular atrial fibrillation: harder to handle than expected.
    Shurlock B
    Eur Heart J; 2014 Jul; 35(28):1825-36. PubMed ID: 25049157
    [No Abstract]   [Full Text] [Related]  

  • 22. Heart failure and atrial fibrillation--does practice meet the anticoagulation guidelines?
    Rewiuk K; Wizner B; Fedyk-Łukasik M; Zdrojewski T; Opolski G; Dubiel JS; Gąsowski J; Grodzicki T
    Int J Cardiol; 2012 May; 157(2):274-5. PubMed ID: 22475842
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
    Gonzalez-Quesada CJ; Giugliano RP
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):111-27. PubMed ID: 24504768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The family doctor and the barriers to prescribing the new oral anticoagulants: heterogeneity, inequality and confusion. Statement of the Spanish Primary Care and Family Medicine Societies].
    Lobos Bejarano JM; Polo García J; Vargas Ortega D
    Semergen; 2014; 40(1):1-3. PubMed ID: 24389167
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ximelagatran or warfarin in atrial fibrillation?
    MacAllister R; Hingorani AD; Casas JP
    Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
    [No Abstract]   [Full Text] [Related]  

  • 27. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism.
    Granger CB; Armaganijan LV
    Circulation; 2012 Jan; 125(1):159-64; discussion 164. PubMed ID: 22215890
    [No Abstract]   [Full Text] [Related]  

  • 28. New oral anticoagulants for atrial fibrillation.
    Spinler SA; Shafir V
    Circulation; 2012 Jul; 126(1):133-7. PubMed ID: 22753535
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent advances in oral anticoagulation for atrial fibrillation.
    Singh M; Adigopula S; Patel P; Kiran K; Khosla S
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):395-407. PubMed ID: 20965952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 31. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
    Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
    Loffredo L; Perri L; Violi F
    Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Should all patients with atrial fibrillation and CHA2DS2-VASc score 1 receive oral anticoagulation?].
    Di Pasquale G; Zagnoni S
    G Ital Cardiol (Rome); 2015 Nov; 16(11):608-12. PubMed ID: 26571473
    [No Abstract]   [Full Text] [Related]  

  • 35. Ximelagatran or warfarin in atrial fibrillation?
    Eikelboom J; Hankey G
    Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
    [No Abstract]   [Full Text] [Related]  

  • 36. ARISTOTLE expands the list of novel anticoagulants for thromboprophylaxis in atrial fibrillation.
    Tzeis S; Andrikopoulos G
    Angiology; 2012 Oct; 63(7):558-9. PubMed ID: 22669951
    [No Abstract]   [Full Text] [Related]  

  • 37. [From warfarin to new oral anticoagulants in clinical practice. What is the future of anticoagulant therapy in atrial fibrillation?].
    Colivicchi F
    Monaldi Arch Chest Dis; 2013 Jun; 80(2):55-6. PubMed ID: 24494406
    [No Abstract]   [Full Text] [Related]  

  • 38. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
    Chan NC; Paikin JS; Hirsh J; Lauw MN; Eikelboom JW; Ginsberg JS
    Thromb Haemost; 2014 May; 111(5):798-807. PubMed ID: 24553904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Novel oral anticoagulants: more opportunities or more risks? And for which patients?].
    Marietta M; Formoso G; Marata AM; Maestri E; Magrini N
    Recenti Prog Med; 2014 Sep; 105(9):333-40. PubMed ID: 25229762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New anticoagulant treatments to protect against stroke in atrial fibrillation.
    Potpara TS; Lip GY; Apostolakis S
    Heart; 2012 Sep; 98(18):1341-7. PubMed ID: 22730480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.